Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report

David M. Maahs; Bruce A. Buckingham; Jessica R. Castle; Ali Cinar; Edward R. Damiano; Eyal Dassau; J. Hans DeVries; Francis J. Doyle; Steven C. Griffen; Ahmad Haidar; Lutz Heinemann; Roman Hovorka; Timothy W. Jones; Craig Kollman; Boris Kovatchev; Brian L. Levy; Revital Nimri; David N. O'Neal; Moshe Philip; Eric Renard; Steven J. Russell; Stuart A. Weinzimer; Howard Zisser; John W. Lum

doi:https://doi.org/10.2337/dc15-2716

Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report

David M. Maahs, Bruce A. Buckingham, Jessica R. Castle, Ali Cinar, Edward R. Damiano, Eyal Dassau, J. Hans DeVries, Francis J. Doyle, Steven C. Griffen, Ahmad Haidar, Lutz Heinemann, Roman Hovorka, Timothy W. Jones, Craig Kollman, Boris Kovatchev, Brian L. Levy, Revital Nimri, David N. O'Neal, Moshe Philip, Eric RenardSteven J. Russell, Stuart A. Weinzimer, Howard Zisser, John W. Lum

Research output: Contribution to journal › Article › Academic › peer-review

189 Citations (Scopus)

Abstract

Research on and commercial development of the artificial pancreas (AP) continue to progress rapidly, and the AP promises to become a part of clinical care. In this report, members of the JDRF Artificial Pancreas Project Consortium in collaboration with the wider AP community 1) advocate for the use of continuous glucose monitoring glucose metrics as outcome measures in AP trials, in addition to HbA1c, and 2) identify a short set of basic, easily interpreted outcome measures to be reported in AP studies whenever feasible. Consensus on a broader range of measures remains challenging; therefore, reporting of additional metrics is encouraged as appropriate for individual AP studies or study groups. Greater consistency in reporting of basic outcome measures may facilitate the interpretation of study results by investigators, regulatory bodies, health care providers, payers, and patients themselves, thereby accelerating the widespread adoption of AP technology to improve the lives of people with type 1 diabetes

Original language	English
Pages (from-to)	1175-1179
Journal	Diabetes Care
Volume	39
Issue number	7
DOIs	https://doi.org/10.2337/dc15-2716
Publication status	Published - 2016

Access to Document

https://doi.org/10.2337/dc15-2716

Cite this

Maahs, D. M., Buckingham, B. A., Castle, J. R., Cinar, A., Damiano, E. R., Dassau, E., DeVries, J. H., Doyle, F. J., Griffen, S. C., Haidar, A., Heinemann, L., Hovorka, R., Jones, T. W., Kollman, C., Kovatchev, B., Levy, B. L., Nimri, R., O'Neal, D. N., Philip, M., ... Lum, J. W. (2016). Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report. Diabetes Care, 39(7), 1175-1179. https://doi.org/10.2337/dc15-2716

@article{35a1a90139c44e6b8fc9a166c9dedf0f,

title = "Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report",

abstract = "Research on and commercial development of the artificial pancreas (AP) continue to progress rapidly, and the AP promises to become a part of clinical care. In this report, members of the JDRF Artificial Pancreas Project Consortium in collaboration with the wider AP community 1) advocate for the use of continuous glucose monitoring glucose metrics as outcome measures in AP trials, in addition to HbA1c, and 2) identify a short set of basic, easily interpreted outcome measures to be reported in AP studies whenever feasible. Consensus on a broader range of measures remains challenging; therefore, reporting of additional metrics is encouraged as appropriate for individual AP studies or study groups. Greater consistency in reporting of basic outcome measures may facilitate the interpretation of study results by investigators, regulatory bodies, health care providers, payers, and patients themselves, thereby accelerating the widespread adoption of AP technology to improve the lives of people with type 1 diabetes",

author = "Maahs, {David M.} and Buckingham, {Bruce A.} and Castle, {Jessica R.} and Ali Cinar and Damiano, {Edward R.} and Eyal Dassau and DeVries, {J. Hans} and Doyle, {Francis J.} and Griffen, {Steven C.} and Ahmad Haidar and Lutz Heinemann and Roman Hovorka and Jones, {Timothy W.} and Craig Kollman and Boris Kovatchev and Levy, {Brian L.} and Revital Nimri and O'Neal, {David N.} and Moshe Philip and Eric Renard and Russell, {Steven J.} and Weinzimer, {Stuart A.} and Howard Zisser and Lum, {John W.}",

year = "2016",

doi = "https://doi.org/10.2337/dc15-2716",

language = "English",

volume = "39",

pages = "1175--1179",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

number = "7",

}

Maahs, DM, Buckingham, BA, Castle, JR, Cinar, A, Damiano, ER, Dassau, E, DeVries, JH, Doyle, FJ, Griffen, SC, Haidar, A, Heinemann, L, Hovorka, R, Jones, TW, Kollman, C, Kovatchev, B, Levy, BL, Nimri, R, O'Neal, DN, Philip, M, Renard, E, Russell, SJ, Weinzimer, SA, Zisser, H & Lum, JW 2016, 'Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report', Diabetes Care, vol. 39, no. 7, pp. 1175-1179. https://doi.org/10.2337/dc15-2716

TY - JOUR

T1 - Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report

AU - Maahs, David M.

AU - Buckingham, Bruce A.

AU - Castle, Jessica R.

AU - Cinar, Ali

AU - Damiano, Edward R.

AU - Dassau, Eyal

AU - DeVries, J. Hans

AU - Doyle, Francis J.

AU - Griffen, Steven C.

AU - Haidar, Ahmad

AU - Heinemann, Lutz

AU - Hovorka, Roman

AU - Jones, Timothy W.

AU - Kollman, Craig

AU - Kovatchev, Boris

AU - Levy, Brian L.

AU - Nimri, Revital

AU - O'Neal, David N.

AU - Philip, Moshe

AU - Renard, Eric

AU - Russell, Steven J.

AU - Weinzimer, Stuart A.

AU - Zisser, Howard

AU - Lum, John W.

PY - 2016

Y1 - 2016

N2 - Research on and commercial development of the artificial pancreas (AP) continue to progress rapidly, and the AP promises to become a part of clinical care. In this report, members of the JDRF Artificial Pancreas Project Consortium in collaboration with the wider AP community 1) advocate for the use of continuous glucose monitoring glucose metrics as outcome measures in AP trials, in addition to HbA1c, and 2) identify a short set of basic, easily interpreted outcome measures to be reported in AP studies whenever feasible. Consensus on a broader range of measures remains challenging; therefore, reporting of additional metrics is encouraged as appropriate for individual AP studies or study groups. Greater consistency in reporting of basic outcome measures may facilitate the interpretation of study results by investigators, regulatory bodies, health care providers, payers, and patients themselves, thereby accelerating the widespread adoption of AP technology to improve the lives of people with type 1 diabetes

AB - Research on and commercial development of the artificial pancreas (AP) continue to progress rapidly, and the AP promises to become a part of clinical care. In this report, members of the JDRF Artificial Pancreas Project Consortium in collaboration with the wider AP community 1) advocate for the use of continuous glucose monitoring glucose metrics as outcome measures in AP trials, in addition to HbA1c, and 2) identify a short set of basic, easily interpreted outcome measures to be reported in AP studies whenever feasible. Consensus on a broader range of measures remains challenging; therefore, reporting of additional metrics is encouraged as appropriate for individual AP studies or study groups. Greater consistency in reporting of basic outcome measures may facilitate the interpretation of study results by investigators, regulatory bodies, health care providers, payers, and patients themselves, thereby accelerating the widespread adoption of AP technology to improve the lives of people with type 1 diabetes

U2 - https://doi.org/10.2337/dc15-2716

DO - https://doi.org/10.2337/dc15-2716

M3 - Article

C2 - 27330126

SN - 0149-5992

VL - 39

SP - 1175

EP - 1179

JO - Diabetes Care

JF - Diabetes Care

IS - 7

ER -